Vagus nerve stimulation therapy summary: five years after FDA approval

Vagus nerve stimulation therapy summary: five years after FDA approval

With more than 16,000 patients implanted with the vagus nerve stimulation (VNS) therapy system (Cyberonics, Inc., Houston, Texas), VNS therapy has assumed an increasingly important role in the treatment of medically refractory seizures since its approval 5 years ago by the United States FDA. This re...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurology 2002-09, Vol.59 (6 Suppl 4), p.S15-S20
1. Verfasser: Schachter, Steven C
Format: Artikel
Sprache:eng
Schlagworte:
Device Approval
Electric Stimulation Therapy - adverse effects
Epilepsy - therapy
Humans
Vagus Nerve - physiology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page S20
container_issue 6 Suppl 4
container_start_page S15
container_title Neurology
container_volume 59
creator Schachter, Steven C
description With more than 16,000 patients implanted with the vagus nerve stimulation (VNS) therapy system (Cyberonics, Inc., Houston, Texas), VNS therapy has assumed an increasingly important role in the treatment of medically refractory seizures since its approval 5 years ago by the United States FDA. This review discusses the clinical trials that provided evidence for the approval, long-term efficacy, efficacy in special populations and co-morbid conditions, and safety and tolerability. Additional studies are suggested to further explore the capabilities of VNS therapy.
doi_str_mv 10.1212/WNL.59.6_suppl_4.S15
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72119581</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72119581</sourcerecordid><originalsourceid>FETCH-LOGICAL-c252t-c5690f652f4294d16d0ac212f099203f6d43c19333cba8e9069ea94279070f263</originalsourceid><addsrcrecordid>eNpFkM1OwzAQhC0EoqXwBgj5xC1hbcdOzK0qFJAqOPB7s9zEhqCkCXZcqW-Pq1Zw2sPOzO58CJ0TSAkl9Or9cZFymQrlQ983KkufCT9AY8KpSASjH4doDECLhBV5MUIn3n8DxGUuj9GIUJqDFGyM5m_6M3i8Mm5tsB_qNjR6qLsVHr6M0_0G-9C22m2usa2jYmO081jbwTg8v5li3feuW-vmFB1Z3Xhztp8T9Dq_fZndJ4unu4fZdJGUlNMhKbmQYAWnNqMyq4ioQJexjAUpKTArqoyVRDLGyqUujAQhjZZZfBpysFSwCbrc5cazP8H4QbW1L03T6JXpglc5JUTygkRhthOWrvPeGat6V2-LKAJqy09FfopL9cdPRX7RdrHPD8vWVP-mPTD2C_61bew</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72119581</pqid></control><display><type>article</type><title>Vagus nerve stimulation therapy summary: five years after FDA approval</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><source>Journals@Ovid Complete</source><creator>Schachter, Steven C</creator><creatorcontrib>Schachter, Steven C</creatorcontrib><description>With more than 16,000 patients implanted with the vagus nerve stimulation (VNS) therapy system (Cyberonics, Inc., Houston, Texas), VNS therapy has assumed an increasingly important role in the treatment of medically refractory seizures since its approval 5 years ago by the United States FDA. This review discusses the clinical trials that provided evidence for the approval, long-term efficacy, efficacy in special populations and co-morbid conditions, and safety and tolerability. Additional studies are suggested to further explore the capabilities of VNS therapy.</description><identifier>ISSN: 0028-3878</identifier><identifier>EISSN: 1526-632X</identifier><identifier>DOI: 10.1212/WNL.59.6_suppl_4.S15</identifier><identifier>PMID: 12270963</identifier><language>eng</language><publisher>United States</publisher><subject>Device Approval ; Electric Stimulation Therapy - adverse effects ; Epilepsy - therapy ; Humans ; Vagus Nerve - physiology</subject><ispartof>Neurology, 2002-09, Vol.59 (6 Suppl 4), p.S15-S20</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c252t-c5690f652f4294d16d0ac212f099203f6d43c19333cba8e9069ea94279070f263</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12270963$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schachter, Steven C</creatorcontrib><title>Vagus nerve stimulation therapy summary: five years after FDA approval</title><title>Neurology</title><addtitle>Neurology</addtitle><description>With more than 16,000 patients implanted with the vagus nerve stimulation (VNS) therapy system (Cyberonics, Inc., Houston, Texas), VNS therapy has assumed an increasingly important role in the treatment of medically refractory seizures since its approval 5 years ago by the United States FDA. This review discusses the clinical trials that provided evidence for the approval, long-term efficacy, efficacy in special populations and co-morbid conditions, and safety and tolerability. Additional studies are suggested to further explore the capabilities of VNS therapy.</description><subject>Device Approval</subject><subject>Electric Stimulation Therapy - adverse effects</subject><subject>Epilepsy - therapy</subject><subject>Humans</subject><subject>Vagus Nerve - physiology</subject><issn>0028-3878</issn><issn>1526-632X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkM1OwzAQhC0EoqXwBgj5xC1hbcdOzK0qFJAqOPB7s9zEhqCkCXZcqW-Pq1Zw2sPOzO58CJ0TSAkl9Or9cZFymQrlQ983KkufCT9AY8KpSASjH4doDECLhBV5MUIn3n8DxGUuj9GIUJqDFGyM5m_6M3i8Mm5tsB_qNjR6qLsVHr6M0_0G-9C22m2usa2jYmO081jbwTg8v5li3feuW-vmFB1Z3Xhztp8T9Dq_fZndJ4unu4fZdJGUlNMhKbmQYAWnNqMyq4ioQJexjAUpKTArqoyVRDLGyqUujAQhjZZZfBpysFSwCbrc5cazP8H4QbW1L03T6JXpglc5JUTygkRhthOWrvPeGat6V2-LKAJqy09FfopL9cdPRX7RdrHPD8vWVP-mPTD2C_61bew</recordid><startdate>20020924</startdate><enddate>20020924</enddate><creator>Schachter, Steven C</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20020924</creationdate><title>Vagus nerve stimulation therapy summary: five years after FDA approval</title><author>Schachter, Steven C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c252t-c5690f652f4294d16d0ac212f099203f6d43c19333cba8e9069ea94279070f263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Device Approval</topic><topic>Electric Stimulation Therapy - adverse effects</topic><topic>Epilepsy - therapy</topic><topic>Humans</topic><topic>Vagus Nerve - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schachter, Steven C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schachter, Steven C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vagus nerve stimulation therapy summary: five years after FDA approval</atitle><jtitle>Neurology</jtitle><addtitle>Neurology</addtitle><date>2002-09-24</date><risdate>2002</risdate><volume>59</volume><issue>6 Suppl 4</issue><spage>S15</spage><epage>S20</epage><pages>S15-S20</pages><issn>0028-3878</issn><eissn>1526-632X</eissn><abstract>With more than 16,000 patients implanted with the vagus nerve stimulation (VNS) therapy system (Cyberonics, Inc., Houston, Texas), VNS therapy has assumed an increasingly important role in the treatment of medically refractory seizures since its approval 5 years ago by the United States FDA. This review discusses the clinical trials that provided evidence for the approval, long-term efficacy, efficacy in special populations and co-morbid conditions, and safety and tolerability. Additional studies are suggested to further explore the capabilities of VNS therapy.</abstract><cop>United States</cop><pmid>12270963</pmid><doi>10.1212/WNL.59.6_suppl_4.S15</doi></addata></record>
fulltext fulltext
identifier ISSN: 0028-3878
ispartof Neurology, 2002-09, Vol.59 (6 Suppl 4), p.S15-S20
issn 0028-3878
1526-632X
language eng
recordid cdi_proquest_miscellaneous_72119581
source MEDLINE; Alma/SFX Local Collection; Journals@Ovid Complete
subjects Device Approval
Electric Stimulation Therapy - adverse effects
Epilepsy - therapy
Humans
Vagus Nerve - physiology
title Vagus nerve stimulation therapy summary: five years after FDA approval
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T23%3A33%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vagus%20nerve%20stimulation%20therapy%20summary:%20five%20years%20after%20FDA%20approval&rft.jtitle=Neurology&rft.au=Schachter,%20Steven%20C&rft.date=2002-09-24&rft.volume=59&rft.issue=6%20Suppl%204&rft.spage=S15&rft.epage=S20&rft.pages=S15-S20&rft.issn=0028-3878&rft.eissn=1526-632X&rft_id=info:doi/10.1212/WNL.59.6_suppl_4.S15&rft_dat=%3Cproquest_cross%3E72119581%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72119581&rft_id=info:pmid/12270963&rfr_iscdi=true